
    
      ANRS 161 L-Vir is a phase III prospective, randomized, multicenter, open-label, superiority
      trial for participants with low-level persistent viremia.

      Participants will be randomized with a 1:1:1 ratio to the following three arms,

        -  Reference arm : counseling without antiretroviral treatment modification

        -  Switch arm : switch of current PI/r for Prezista® (darunavir)/ Norvir® (ritonavir)
           (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with
           counseling.

        -  Addition of Isentress® (raltégravir) arm : Isentress® (raltegravir) 400 mg two times a
           day (BID) added to current antiretroviral treatment with counseling
    
  